A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The goal of this study is to evaluate the safety, tolerability and immunogenicity of ascending doses of adjuvant in combination with a single dosage level of RSV sF in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions. This study will also provide preliminary safety and immunogenicity data to support concurrent dosing of MEDI7510 with influenza vaccine (IIV), and to assess the safety of MEDI7510 at a dose previously assessed in the Phase 1a study.
Epistemonikos ID: 0b1f5388dfb43bba18c452f8d8fd1bd3bcf9ab24
First added on: Mar 23, 2020